{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:07:05Z","timestamp":1747400825389,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#82060300"],"award-info":[{"award-number":["#82060300"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["#2020GXNSFAA297146"],"award-info":[{"award-number":["#2020GXNSFAA297146"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare the efficacy and safety between baricitinib (BARI) and tofacitinib (TOFA) for the treatment of the rheumatoid arthritis (RA) patients receiving methotrexate (MTX) in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study recruited 179 RA patients treated with BARI (2\u20134\u00a0mg\/d) or TOFA (10\u00a0mg\/d) at The First Affiliated Hospital of Guangxi Medical University from September 2019 to January 2022. The rate of low disease activity (LDA) was used as the primary end point. Secondary end points included the Disease Activity Scale-28 (DAS-28)-C-reactive protein (CRP); the rate of DAS28-CRP remission; visual analogue scale (VAS) for pain, swollen joint, and tender joint counts; and adverse events at the 6-month follow-up. Several factors affecting LDA achievement were also analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-four patients were treated with BARI and 105 were treated with TOFA, including 83.24% females, with a median (IQR) age of 56.0 (53.0\u201356.0) years old and disease duration of 12.0 (6.0\u201312.0) months. There was no difference of the rate of LDA between the BARI and TOFA treatment groups. All disease indices in the two groups were significantly improved, including a significantly lower VAS in the BARI group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), reflecting the drug efficacy after 1 and 6 months of treatment. The incidence of adverse reactions was similar in these two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The treatment efficacy and safety of BARI and TOFA in the RA patients were similar, but BARI was more effective in pain relief than TOFA. An older baseline age was more likely to achieve LDA in the BARI group, while a low baseline erythrocyte sedimentation rate (ESR) was more likely to achieve LDA in the TOFA group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-023-00331-1","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T16:02:12Z","timestamp":1697472132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial"],"prefix":"10.1186","volume":"63","author":[{"given":"Xiaoling","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-7740","authenticated-orcid":false,"given":"Ling","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"issue":"10086","key":"331_CR1","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet (London England). 2017;389(10086):2328\u201337.","journal-title":"Lancet (London England)"},{"issue":"1","key":"331_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"331_CR3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360\u201372.","journal-title":"JAMA"},{"key":"331_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human Disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"issue":"12","key":"331_CR5","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354\u201361.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"331_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559\u201370.","journal-title":"Arthritis Rheum"},{"issue":"9865","key":"331_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet (London England). 2013;381(9865):451\u201360.","journal-title":"Lancet (London England)"},{"issue":"7","key":"331_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"},{"key":"331_CR9","unstructured":"[2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]. Zhonghua nei ke za zhi. 2018;57(4):242 \u2013 51."},{"issue":"1","key":"331_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3899\/jrheum.191252","volume":"48","author":"A Fisher","year":"2021","unstructured":"Fisher A, Hudson M, Platt RW, Dormuth CR. Canadian Network for Observational Drug Effect Studies I. Tofacitinib persistence in patients with rheumatoid arthritis: a retrospective cohort study. J Rheumatol. 2021;48(1):16\u201324.","journal-title":"J Rheumatol"},{"key":"331_CR11","doi-asserted-by":"crossref","unstructured":"Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B et al. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: results from the RA-BEAM trial. J Clin Med. 2019;8(6).","DOI":"10.3390\/jcm8060831"},{"issue":"7","key":"331_CR12","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s10067-021-05609-7","volume":"40","author":"K Ebina","year":"2021","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al. Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clin Rheumatol. 2021;40(7):2673\u201380.","journal-title":"Clin Rheumatol"},{"key":"331_CR13","doi-asserted-by":"crossref","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580\u20138.","DOI":"10.1136\/ard.2010.138461"},{"issue":"10055","key":"331_CR14","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet (London England). 2016;388(10055):2023\u201338.","journal-title":"Lancet (London England)"},{"issue":"6","key":"331_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953\u201362.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"331_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","volume":"25","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25(4):514\u201321.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"331_CR17","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.18553\/jmcp.2016.22.12.1457","volume":"22","author":"J Harnett","year":"2016","unstructured":"Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with Tofacitinib compared with Adalimumab, Etanercept, and Abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Managed care Specialty Pharm. 2016;22(12):1457\u201371.","journal-title":"J Managed care Specialty Pharm"},{"issue":"5","key":"331_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2169\/internalmedicine.9341-17","volume":"57","author":"S Mori","year":"2018","unstructured":"Mori S, Yoshitama T, Ueki Y. Tofacitinib Therapy for Rheumatoid Arthritis: a direct comparison study between Biologic-na\u00efve and experienced patients. Intern Med (Tokyo Japan). 2018;57(5):663\u201370.","journal-title":"Intern Med (Tokyo Japan)"},{"issue":"1","key":"331_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"331_CR20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"331_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40744-021-00423-8","volume":"9","author":"B Hern\u00e1ndez-Cruz","year":"2022","unstructured":"Hern\u00e1ndez-Cruz B, Rosas J, D\u00edaz-Torn\u00e9 C, Belzunegui J, Garc\u00eda-Vicu\u00f1a R, Inciarte-Mundo J, et al. Real-world treatment patterns and clinical outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: results of a Multicenter, Observational Study in Routine Clinical Practice (the ORBIT-RA study). Rheumatol Therapy. 2022;9(2):589\u2013608.","journal-title":"Rheumatol Therapy"},{"issue":"7","key":"331_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"331_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/1744666X.2022.2064275","volume":"18","author":"AI Venetsanopoulou","year":"2022","unstructured":"Venetsanopoulou AI, Voulgari PV, Drosos AA. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Rev Clin Immunol. 2022;18(5):485\u201393.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"331_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jcpt.13142","volume":"45","author":"Y Ho Lee","year":"2020","unstructured":"Ho Lee Y, Gyu Song G. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. J Clin Pharm Ther. 2020;45(4):674\u201381.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"331_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00393-020-00750-1","volume":"79","author":"YH Lee","year":"2020","unstructured":"Lee YH, Song GG. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol. 2020;79(8):785\u201396.","journal-title":"Z Rheumatol"},{"issue":"9","key":"331_CR26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","volume":"80","author":"Y Miyazaki","year":"2021","unstructured":"Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Inoue Y, Fujino Y, et al. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Ann Rheum Dis. 2021;80(9):1130\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"331_CR27","first-page":"e27638","volume":"2","author":"M Busch-Dienstfertig","year":"2013","unstructured":"Busch-Dienstfertig M, Gonzalez-Rodriguez S. IL-4, JAK-STAT signaling, and pain. JAKSTAT. 2013;2(4):e27638.","journal-title":"JAKSTAT"},{"issue":"5","key":"331_CR28","doi-asserted-by":"publisher","first-page":"R199","DOI":"10.1186\/ar4037","volume":"14","author":"AD Cook","year":"2012","unstructured":"Cook AD, Pobjoy J, Steidl S, D\u00fcrr M, Braine EL, Turner AL, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and Disease development. Arthritis Res Therapy. 2012;14(5):R199.","journal-title":"Arthritis Res Therapy"},{"issue":"1","key":"331_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1471-4159.2008.05566.x","volume":"107","author":"E Dominguez","year":"2008","unstructured":"Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M. JAK\/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J Neurochem. 2008;107(1):50\u201360.","journal-title":"J Neurochem"},{"key":"331_CR30","doi-asserted-by":"crossref","unstructured":"Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, De Leonardis F et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naive to treatment with biologic or conventional synthetic disease-modifying antirheumatic Drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1).","DOI":"10.1136\/rmdopen-2019-001131"},{"key":"331_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fmed.2018.00185","volume":"5","author":"CK Orr","year":"2018","unstructured":"Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, et al. The Utility and limitations of CRP, ESR and DAS28-CRP in appraising Disease Activity in Rheumatoid Arthritis. Front Med. 2018;5:185.","journal-title":"Front Med"},{"issue":"9","key":"331_CR32","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","volume":"60","author":"J Fitton","year":"2021","unstructured":"Fitton J, Melville AR, Emery P, Nam JL, Buch MH. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology (Oxford). 2021;60(9):4048\u201354.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"331_CR33","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","volume":"58","author":"M Harigai","year":"2019","unstructured":"Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i34\u2013i42.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"331_CR34","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"331_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00575-5","volume":"17","author":"SB Cohen","year":"2021","unstructured":"Cohen SB. JAK inhibitors and VTE risk: how concerned should we be? Nat Rev Rheumatol. 2021;17(3):133\u20134.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"331_CR36","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/annrheumdis-2013-203380","volume":"73","author":"WS Chung","year":"2014","unstructured":"Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein Thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73(10):1774\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"331_CR37","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449\u201355.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"331_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"331_CR39","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1056\/NEJMc2202778","volume":"386","author":"A Ozdede","year":"2022","unstructured":"Ozdede A, Yazici H. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(18):1766.","journal-title":"N Engl J Med"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00331-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-023-00331-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00331-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T22:02:07Z","timestamp":1700258527000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-023-00331-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["331"],"URL":"https:\/\/doi.org\/10.1186\/s42358-023-00331-1","relation":{},"ISSN":["2523-3106"],"issn-type":[{"type":"electronic","value":"2523-3106"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with a protocol approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Xiaoling Liao, Wang Huo, Wen Zeng, Fang Qin, Fei Dong, Wanling Wei, and Ling Lei declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}